A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
The goal of the study is to measure and compare the levels of nemtabrutinib in the blood after taking different forms of nemtabrutinib orally on an empty stomach (fasted) to see if they are the same or different.
Hematological Malignancy
DRUG: Nemtabrutinib
Parts 1 and 2: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Nemtabrutinib, Blood samples will be collected to determine the AUC0-inf of nemtabrutinib., At designated time points (up to approximately 2 weeks)|Parts 1 and 2: Maximum Plasma Concentration (Cmax) of Nemtabrutinib, Blood samples will be collected to determine the Cmax of nemtabrutinib., At designated time points (up to approximately 2 weeks)
Number of Participants Who Experience an Adverse Event (AE), An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported., Up to approximately 2 months|Number of Participants Who Discontinue Study Due to an AE, An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported., Up to approximately 2 months
The goal of the study is to measure and compare the levels of nemtabrutinib in the blood after taking different forms of nemtabrutinib orally on an empty stomach (fasted) to see if they are the same or different.